Sandoz Group
SDZ.SWApprovedSandoz Group is a global leader in generic and biosimilar medicines, spun off from Novartis in 2023 to operate as an independent publicly-traded company. The company focuses on providing affordable access to medicines through its extensive portfolio of generic drugs and biosimilar versions of complex biologics across multiple therapeutic areas.
SDZ.SW · Stock Price
Historical price data
AI Company Overview
Sandoz Group is a global leader in generic and biosimilar medicines, spun off from Novartis in 2023 to operate as an independent publicly-traded company. The company focuses on providing affordable access to medicines through its extensive portfolio of generic drugs and biosimilar versions of complex biologics across multiple therapeutic areas.
Technology Platform
Generic drug development and biosimilar manufacturing with expertise in complex formulations and biologics
Pipeline Snapshot
129129 drugs in pipeline, 33 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| pramipexole + Bromocriptine | Parkinson's Disease | Approved |
| Omnitrope | Small for Gestational Age | Approved |
| HX575 recombinant human erythropoietin alfa | Chronic Kidney Disease | Approved |
| Levodopa/Carbidopa(200mg/50mg) + Dopaminergic Agonists | Impulse Control Disorder | Approved |
| Filgrastim | Severe Chronic Neutropenia | Approved |
Funding History
1FDA Approved Drugs
32Opportunities
Risk Factors
Competitive Landscape
Sandoz competes against major generics companies like Teva, Viatris, and regional players, differentiating through its focus on complex generics, biosimilar expertise, and global manufacturing capabilities. The market remains highly fragmented with ongoing consolidation pressures.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile